'Filipino woman' with suicide vests: PHL govt treads warily, migrants seek speedy action 04-Oct-15, 6:25 PM | | Agence France-Presse | With Carla Lim, News5

Vatican theologian comes out of closet on eve of bishops meet 04-Oct-15, 2:17 AM | Laure Brumont, Angus MacKinnon, Agence France-Presse

REFLECTION | Jesus on marriage: ‘Stay committed’ 04-Oct-15, 12:28 PM | By Rev. Fr. Christian B. Buenafe, O. Carm. | Lifestyle Section,

'Yaya Dub,' 'Lola Nidora' invited as guest speakers in this year's Catholic Social Media Summit 04-Oct-15, 7:22 AM | Ferdinand G. Patinio, Philippines News Agency

Several VW engineers admit to installing cheat device: report 04-Oct-15, 5:06 PM | Agence France-Presse

Science | World

Can companies patent human genes? US Supreme Court will take up the question
The online news portal of TV5

WASHINGTON - The US Supreme Court said Friday it would examine whether companies should be able to patent human genes they have isolated and identified, a decision that could have far-reaching implications for genetic research.

An appeals court in August authorized a biotechnology company, Myriad Genetics Inc., to patent two genes it found had links to breast and ovarian cancer - women with the gene were at a much higher risk of developing the cancers.

These patents give Myriad the exclusive right to create and distribute commercial screenings for the two genes.

But a wide-ranging group of plaintiffs - including molecular research teams, doctors, patients and the American Civil Liberties Union - have asked the Supreme Court to invalidate the ruling.

They argue the decision to allow certain genes to be patented would slam the brakes on scientific research, as well as restrict access to care.

"DNA occurs naturally in the human body and cannot be patented by a single company that can then use its patents to limit scientific research and the free exchange of ideas," said Chris Hansen, lawyer for the American Civil Liberties Union, or ACLU, which filed an appeal.

Myriad maintains, however, that the discovery of the two genes, the product of research that typically requires years of effort and large investments, ought to be protected.

The Supreme Court will hear arguments in March and render its decision in June.